Show an ad over header. AMP

The challenge of 2021: Vaccinating the world

Vaccinating the world will be perhaps the single greatest global challenge of 2021, and that process is now beginning in earnest.

The big picture: If you're reading this in Europe, the U.S. or one of several other wealthy countries, you will probably have access to a vaccine in 2021. But if you're in a lower-income country, particularly in sub-Saharan Africa, you could be waiting until 2023.

The first vaccines to gain regulatory approval in the West — from Pfizer/BioNTech and Moderna — are bound almost exclusively for wealthy countries, at least in the near term.

  • Many rich countries have hedged their bets by buying enough doses of several different vaccine candidates to cover their populations even if some candidates aren't approved.

By the numbers

At least 7.7 billion vaccine doses have already been purchased, with another 3.9 billion reserved should countries or blocs elect to expand their orders, according to Duke University's tracker.

  • If you combine both categories, the U.S. has reserved nearly one-quarter of the global supply with 2.6 billion doses.
  • Not a single country in sub-Saharan Africa has announced a deal to purchase vaccine doses, though Johnson & Johnson is aiming to produce 300 million doses in South Africa next year.
Data: Duke Global Health Innovation Center; Chart: Axios Visuals

It's not just that access to doses varies wildly by income level — richer countries are also buying different vaccines than poorer ones.

  • India is home to the world's largest vaccine manufacturer, and has sealed massive deals to begin to cover its population of nearly 1.4 billion.
  • Those deals are with Novavax, which has yet to release efficacy data, and AstraZeneca, whose vaccine appears to be about 70% effective but is undergoing further evaluation and testing.
  • The EU has purchased roughly the same number of doses but has a much more diversified portfolio. It includes 300 million doses of the Pfizer vaccine, the first shipments of which will begin on Thursday.
  • Several developing countries have struck deals for just one vaccine candidate, often from Russia (as with Kazakhstan, Nepal and Venezuela) or China.

Breaking it down: A forecast from The Economist Intelligence Unit projects that the most fortunate countries — including the U.S., U.K., EU and Japan — will spend the first half of 2021 vaccinating priority groups and the second half of the year vaccinating the remainder of their populations.

  • In other high-income countries — as well as in countries like China, Brazil, India and Russia that are producing or manufacturing vaccines at scale — mass vaccinations will begin next year but likely continue into early 2022.
  • Other middle-income countries aren’t expected to be able to vaccinate all high-priority groups until late 2021, with mass vaccinations continuing throughout 2022.
  • Low-income countries that can’t afford to purchase doses in bulk will still be vaccinating high-priority groups into early 2022, with mass vaccinations continuing throughout 2023 and perhaps into 2024.

What to watch

There are a number of variables that could shift that outlook significantly in either direction.

1. Further announcements on the safety, efficacy and scalability of additional vaccines, including those from Oxford/AstraZeneca, J&J, Novavax and Sanofi, which have together committed more than 2 billion doses to developing countries.

2. More news on Russia's Sputnik V vaccine and on the several vaccines in development in China.

3. The ability to increase manufacturing capacity in the developing world, and to build strong supply chains to ship and distribute doses globally.

4. The efficient distribution of unused doses by rich countries to poorer ones.

5. The engagement of the Biden administration. President-elect Biden has said he'll re-engage with the World Health Organization and restore America's global leadership, but he hasn't spoken about a U.S. role in global vaccine distribution.

State of play

The single biggest factor will be the success of the COVAX initiative, from the Gavi vaccine alliance, the Coalition for Epidemic Preparedness Innovations and the WHO.

Driving the news: Those groups told reporters in a briefing on Friday that they're on track to meet their ambitious goal of ensuring at least 20% of the population in virtually every country on earth has access to a vaccine by the end of 2021.

The big picture: COVAX is the only route to a vaccine for dozens of countries, and wealthier participants will effectively subsidize their access.

What to watch: The aim for the first half of 2021 is to provide enough doses to all participant countries to cover frontline health and social care workers.

  • Then comes the 20% wave, which is intended to reach the most vulnerable people in each country.
  • Dr. Krishna Udayakumar, director of Duke's Global Health Innovation Center, says the 20% target will be very difficult to hit next year, and 60%-70% vaccination rates — the target for herd immunity — are unlikely before the end of 2022 even in a best-case scenario.
  • Yes, but: Vaccinating the most vulnerable and combining vaccination with other public health measures to slow the spread will allow "a real reduction in death and disability but also really an uptick in economic activity," he adds.

Off the rails: Inside Air Force One ahead of Trump's last stand in Georgia

Beginning on election night 2020 and continuing through his final days in office, Donald Trump unraveled and dragged America with him, to the point that his followers sacked the U.S. Capitol with two weeks left in his term. Axios takes you inside the collapse of a president with a special series.

Episode 6: Georgia had not backed a Democratic presidential candidate since 1992 and Donald Trump's defeat in this Deep South stronghold, and his reaction to that loss, would help cost Republicans the U.S. Senate as well. Georgia was Trump's last stand.

On Air Force One, President Trump was in a mood. He had been clear he did not want to return to Georgia, and yet somehow he'd been conscripted into another rally on the night of Jan. 4.

If both David Perdue and Kelly Loeffler — the two embattled Georgia senators he was campaigning for — lost their runoff elections the following day, the GOP would lose control of the U.S. Senate. And Trump did not want the blood of Georgia on his hands.

Keep reading... Show less

Parler shows signs of life

Far-right-friendly social network Parler is beginning to resurface after going dark last week following a series of bans by Google, Apple and Amazon.

The big picture: By getting a new internet provider that's friendly to far-right sites, Parler — home to a great deal of pro-insurrection chatter before, during and after the Capitol siege — may have found a way to survive despite Big Tech's efforts to pull the plug.

Keep reading... Show less

Historian Michael Beschloss: Trump has "no business" dictating who is an American hero

Data: Trump Executive Order and Axios reporting. Chart: Danielle Alberti/Axios

Delivering on a promise he made at Mount Rushmore this summer, President Trump yesterday released his 244 candidates for a "National Garden of American Heroes."

By the numbers: Men outnumber women nearly four to one (192 to 52). 86 of the nominees,nearly a third, were born between 1900 and 1950. 

Keep reading... Show less

Demand for coronavirus vaccines is outstripping supply — as expected

Now that nearly half of the U.S. population could be eligible for coronavirus vaccines, America is facing the problem experts thought we’d have all along: demand for the vaccine is outstripping supply.

Why it matters: The Trump administration’s call for states to open up vaccine access to all Americans 65 and older and adults with pre-existing conditions may have helped massage out some bottlenecks in the distribution process, but it’s also led to a different kind of chaos.

Keep reading... Show less

First look: Mayors press Biden on immigration

A coalition of nearly 200 mayors and county executives is challenging Joe Biden and the incoming Congress to adopt a progressive immigration agenda that would give everyone a pathway to citizenship.

Why it matters: The group's goals, set out in a white paper released today, seem to fall slightly to the left of what the president-elect plans to propose on Inauguration Day — though not far — and come at a time of intense national polarization over immigration.

Keep reading... Show less

Woman who allegedly stole laptop from Pelosi's office to sell to Russia is arrested

A woman accused of breaching the Capitol and planning to sell to Russia a laptop or hard drive she allegedly stole from Speaker Nancy Pelosi's office was arrested in Pennsylvania's Middle District Monday, the Department of Justice said.

Driving the news: Riley June Williams, 22, is charged with illegally entering the Capitol as well as violent entry and disorderly conduct. She has not been charged over the laptop allegation and the case remains under investigation, per the DOJ.

Keep reading... Show less

Biden will reverse Trump's attempt to lift travel restrictions from Europe and Brazil

The incoming Biden administration will reverse President Trump's last-minute order to lift COVID-19 related travel restrictions, Jen Psaki, the incoming White House press secretary, tweeted.

Why it matters: President Trump ordered entry bans lifted for travelers from the U.K., Ireland, Brazil and much of Europe to go into effect Jan. 26, but the Biden administration will "strengthen public health measures around international travel in order to further mitigate the spread of COVID-19," Jen Psaki said. Biden will be inaugurated on Wednesday, Jan. 20 and Trump will no longer be president by the time the order is set to go into effect.

Keep reading... Show less

Dominion sends cease and desist letter to My Pillow CEO Mike Lindell

Dominion Voting Systems on Monday sent a cease and desist letter to My Pillow CEO Mike Lindell over his spread of misinformation related to the 2020 election.

Why it matters: Trump and several of his allies have pushed false conspiracy theories about the company, leading Dominion to take legal action. It's suing pro-Trump lawyer Sydney Powell for defamation and $1.3 billion in damages, and a Dominion employee has sued Trump himself, OANN and Newsmax.

Keep reading... Show less



Get Goodhumans in your inbox

Most Read

More Stories